Drugs / Shan 5
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00877357 | Jan 2009 → Dec 2012 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Shantha Biotechnics Limited | Unknown | No outcome recorded |
| Phase 4 | NCT00674908 | Mar 2008 → Mar 2009 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Shantha Biotechnics Limited | Completed | No outcome recorded |
| Phase 4 | NCT00617812 | Mar 2008 → Apr 2009 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Shantha Biotechnics Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shan 5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00674908 ↗ |
| Modality | Vaccine | “Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine” NCT00617812 ↗ |